Skip to content
  • Careers
  • Blog
  • Contact Us
  • English
    • French
    • German
Nexelis, a Q² Solutions Company
  • What’s Next
  • Our Services
    • Early Development Assays
    • Preclinical
    • Protein Sciences
    • Bioanalytical Services
      • Menu
    • Biomarkers
      • Menu
    • Translational Sciences
    • Assay Development and Technology Transfer
    • High-Throughput Testing
  • Our Expertise
    • Infectious Diseases
      • Vaccine
      • COVID-19
    • Immunotherapy
      • Immuno-oncology
    • Metabolic Diseases
  • About Us
    • About Us
    • Our Sites
      • Laval
      • Seattle
      • Gosselies
      • Indianapolis
      • Marburg
      • Porton Down
    • Our Scientists
  • News & Events
    • News
    • Events
  • Resources

Poster

Poster

Development of an Intestinal Tissue Bioanalytical Assay Method

Poster

Evaluation of Degradation Products of Insulin using High Resolution Mass Spectrometry

Poster

Evaluation of Degradation Products of Insulin using High Resolution Mass Spectrometry with Proteome Discoverer(TM) and BioPharma Finder (TM)

Poster

Development and Validation of a UHPLC/MS/MS Method for a Panel of Drugs and Metabolites to Support Drug-Drug Interaction Studies

Poster

Anti-Drug Antibody Data Management using E-Workbook

Poster

Measurement of Lidocaine and 2,6-DMA in Minipig Plasma, Skin, and Dermal Tapes Using UHPLC with Electrospray MS/MS

Poster

Method Development and Pharmacokinetic Analysis of a Controlled Release Formulation of Bupivicaine, LIQ865A, in Rats and Minipigs

Poster

Development of an LC-MS/MS Method Midazolam and 1-OH Midazolam

Poster

Bioanalytical Analysis of Sunitinib Microparticles for Ocular Administration

Poster

Development of LC-MS/MS Methods in Plasma for SPR741, a Cyclic Nonapeptide Which Potentiates Antibiotic Activity Against Gram-negative Pathogens

Posts navigation

Older posts
About Nexelis, a Q² Solutions Company

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q² Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

A Q2 Solutions Company


Contact Us

Q2 Solutions, a wholly owned subsidiary and laboratory division of IQVIA, is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository and specimen management, and clinical trial sample and consent tracking solutions. Learn more at www.q2labsolutions.com.

Contact Us

Careers
Quality Assurance
Information Technology

Follow Us LinkedIn Twitter YouTube

© 2022 Nexelis, a Q² Solutions Company. All Rights Reserved.

  • Legal & Compliance
  • Terms of Use
  • What’s Next
  • Our Services
    • Early Development Assays
    • Preclinical
    • Protein Sciences
    • Bioanalytical Services
      • Menu
    • Biomarkers
      • Menu
    • Translational Sciences
    • Assay Development and Technology Transfer
    • High-Throughput Testing
  • Our Expertise
    • Infectious Diseases
      • Vaccine
      • COVID-19
    • Immunotherapy
      • Immuno-oncology
    • Metabolic Diseases
  • About Us
    • About Us
    • Our Sites
      • Laval
      • Seattle
      • Gosselies
      • Indianapolis
      • Marburg
      • Porton Down
    • Our Scientists
  • News & Events
    • News
    • Events
  • Resources
  • Careers
  • Blog
  • Contact Us
  • English
    • French
    • German